Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02679508
Other study ID # Vonoprazan-4003
Secondary ID U1111-1178-8948J
Status Completed
Phase Phase 4
First received
Last updated
Start date March 20, 2016
Est. completion date March 5, 2022

Study information

Verified date December 2023
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment after healed erosive esophagitis (EE), and the curative effect of vonoprazan 20 mg versus lansoprazole in patients with EE.


Description:

This is a multicenter, open-label, randomized, parallel-group study to exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration of vonoprazan in maintenance treatment after healed EE, and the curative effect of vonoprazan versus lansoprazole in participants with EE. Participants endoscopically diagnosed with EE of Los Angeles (LA) Classification Grades A to D at the start of treatment (Week 0 of the healing phase) will be randomly assigned to receive either vonoprazan 20 mg or lansoprazole 30 mg to be taken once daily for up to 8 weeks. Subjects with healed EE as confirmed endoscopically at Week 4 or 8 in the healing phase will enter the maintenance phase. In the maintenance phase, the vonoprazan group and the lansoprazole group will be administered a starting dose of 10 mg and 15 mg, respectively, once daily up to 260 weeks. If the principal investigator or investigator judged the effect of vonoprazan 10 mg or lansoprazole 15 mg to be insufficient as the maintenance treatment of EE, vonoprazan and lansoprazole may be increased to 20 mg and 30 mg, respectively. The research period will consist of two subperiods: healing phase in which participants with EE will receive treatment (for 4 or 8 weeks) and maintenance phase in which participants will receive maintenance treatment (for 260 weeks), and thus, a total of up to 268 weeks. The number of visits will be a maximum of 18 visits. Planned number of research subjects, as the number of research subjects for entry to the maintenance phase, will be 130 participants in the vonoprazan group and 65 participants in the lansoprazole group.


Recruitment information / eligibility

Status Completed
Enrollment 208
Est. completion date March 5, 2022
Est. primary completion date March 5, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria Healing Phase: 1. Participants endoscopically diagnosed with EE of grades A to D by the LA Classification Grading System at the start of treatment (Week 0 of the healing phase) 2. Participants with H. pylori negative 3. Participants who, in the opinion of the principal investigator or investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements. 4. Participants who can sign and date an informed consent form and information sheet prior to the conduction of the clinical research procedures. 5. Male or female participants aged 20 years or older at the time of informed consent 6. Therapeutic category: Ambulatory Maintenance Phase: 7. Participants who have endoscopically confirmed EE healing* (mucous membrane disorder is not observed) at completion of the healing phase (Week 4 or 8 of the healing phase) * Participants who are classified as grade 0 according to severity classification of EE (See Table 9.b) 8. Participants who have been determined to be appropriate as subjects for maintenance treatment of EE by the principal investigator or investigator Exclusion Criteria: Healing Phase: 1. Participants with concurrent peptic ulcer (except scarred stage) or Zollinger-Ellison syndrome 2. Participants who received treatment with PPIs (including vonoprazan) within 4 weeks (Week -4 to Week 0) prior to the start of healing phase (Week 0 of the healing phase) 3. Participants with a history of H. pylori eradication. 4. Participants who have received surgery or treatment affecting gastroesophageal reflux (fundoplication or dilation for esophageal stenosis [excluding Schatzki's ring], etc.) 5. Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included. 6. Participants with clinically apparent hepatic impairment (e.g., AST or ALT levels at the time of informed consent: >1.5 times the upper limit of normal (ULN). 7. Participants with renal impairment or renal failure [creatinine clearance (CCr) ?30 mL/min, etc.] 8. Participants with a history of hypersensitivity or allergy for PPIs. 9. Participants with a history of gastrectomy, gastrointestinal resection, or vagotomy 10. Participants with a malignant tumor 11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant 12. Participants with one of the diseases listed under administration contraindication in the vonoprazan or lansoprazole package insert 13. Participants planning to take prohibited concomitant medications during the research period 14. Participants participating in other clinical studies 15. Participants who have been determined to be inappropriate as subjects in the study by the principal investigator or investigator Maintenance Phase: 16. Participants who have taken PPIs other than the study drug or the control drug during the healing phase 17. Participants who have been determined to be inappropriate as subjects in the study by the principal investigator or investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vonoprazan
Vonoprazan fumarate 10 mg or 20 mg capsules
Lansoprazole
Lansoprazole 15 mg or 30 mg capsules

Locations

Country Name City State
Japan Tokatsu Tsujinaka Hospital Abiko Chiba
Japan Shin-Beppu Hospital Beppu Oita
Japan Juntendo University Hospital Bunkyo-ku Tokyo
Japan Chihaya Hospital Fukuoka
Japan Harada Hospital Fukuoka
Japan Kimura Shiro Clinic Fukuoka
Japan Kyushu University Hospital Fukuoka
Japan Mori Clinic Fukuoka
Japan Hakodate Hospital Hakodate Hokkaido
Japan Hohnodai Hospital National Center For Global Health and Medicine Ichikawa Chiba
Japan Shimane University Hospital Izumo Shimane
Japan Juntendo University Shizuoka Hospital Izunokuni Shizuoka
Japan Kawakubo Clinic Kama Fukuoka
Japan Aoyama Medical Clinic Kobe Hyogo
Japan Hanabata Clinic Kumamoto
Japan Morinaga Ueno Clinic Kumamoto
Japan Kawasaki Medical University Kurashiki Okayama
Japan Oki Hospital Kyoto
Japan Red Cross Matsuyama Hospital Matsuyama Ehime
Japan Hyogo College Of Medicine Nishinomiya Hyogo
Japan Arita Hospital Oita
Japan Asahigaoka Hospital Okayama
Japan Kawasaki Hospital Okayama
Japan Banno Clinic Ota-ku Tokyo
Japan Masuyama Clinic Otawara Tochigi
Japan Shiga Hospital Otsu Shiga
Japan Shiga University Of Medical Science Hospital Otsu Shiga
Japan Shirane Clinic Sendai Miyagi
Japan Tohoku University Hospital Sendai Miyagi
Japan Shimokitazawa Tomo Clinic Setagaya-ku Tokyo
Japan National Center For Global Health and Medicine Shinjyuku-ku Tokyo
Japan Nippon Medical School Hospital Shinjyuku-ku Tokyo
Japan Matsuki Clinic Shizuoka
Japan KKR Takamatsu Hospital Takamatsu Kagawa
Japan Kohga Hospital Yaizu Shizuoka
Japan Oizumi Medical Clinic Yamagata

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Malignant Alteration of Epithelial Cells Numbers of participants with malignant alteration of epithelial cells for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. Time Frame: Up to Week 268 (Week 260 in Maintenance Phase)
Primary Number of Participants With Parietal Cell Protrusion/Hyperplasia Numbers of participants with parietal cell protrusion/hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Primary Number of Participants With Foveolar Hyperplasia Numbers of participants with foveolar hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Primary Number of Participants With Enterochromaffin-like-cell Hyperplasia Numbers of participants with enterochromaffin-like-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Primary Number of Participants With G-cell Hyperplasia Numbers of participants with G-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Percentage of Participants With Recurrence of Erosive Esophagitis (EE) Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades O and A to D) during the Maintenance Phase. The LA classification graded as follows- Grade O: normal mucosa; Grade A: nonconfluent mucosal breaks <5 mm in length; Grade B: nonconfluent mucosal breaks = 5mm in length; Grade C: confluent mucosal breaks <75% circumferential; Grade D: confluent mucosal breaks >75% circumferential. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Percentage of Participants Who Healed EE at the End of Healing Phase Percentage of participants who healed EE at the end of healing phase was reported. Up to Week 8
Secondary Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase Number of participants reporting one or more TEAEs in Maintenance Phase was reported. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. 260 weeks (Baseline, up to the end of Maintenance Phase)
Secondary Number of Participants With Fundic Gland Polyp Numbers of participants with fundic gland polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Hyperplastic Polyp Numbers of participants with hyperplastic polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Cobblestone Mucosa Numbers of participants with cobblestone mucosa for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Multiple White and Flat Elevated Lesions Numbers of participants with multiple white and flat elevated lesions for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Black Spots Numbers of participants with black spots for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body Numbers of participants with neutrophilic infiltration in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum Numbers of participants with neutrophilic infiltration in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body Numbers of participants with atrophy in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Atrophy in Greater Curvature of Antrum Numbers of participants with atrophy in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body Numbers of participants with intestinal metaplasia in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum Numbers of participants with intestinal metaplasia in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body Numbers of participants with presence of H.pylori in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum Numbers of participants with presence of H.pylori in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. Up to Week 268 (Week 260 in Maintenance Phase)
Secondary Number of Participants With Gastric Polyp Numbers of participants with gastric polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported. The number analyzed is the number of participants with data available for analysis. Up to Week 268 (Week 260 in Maintenance Phase)
See also
  Status Clinical Trial Phase
Completed NCT01452776 - Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Recruiting NCT05587309 - A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis Phase 3
Completed NCT04124926 - Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Phase 3
Completed NCT01459367 - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT01499368 - A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients Phase 3
Not yet recruiting NCT04613895 - Treatment Effect According to Timing of Administration of DWP14012 40 mg N/A
Recruiting NCT02615184 - A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children Phase 2
Completed NCT02456935 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02028663 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 2
Completed NCT03006874 - Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02388724 - Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Phase 3
Completed NCT01865825 - Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? N/A
Recruiting NCT06391177 - A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily Phase 1
Completed NCT05050188 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 Phase 1
Completed NCT01874535 - Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Phase 4
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Completed NCT01630746 - A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis Phase 3
Completed NCT01642615 - Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents Phase 2
Completed NCT01509261 - Efficacy Study of Ilaprazole to Treat Erosive Esophgitis Phase 3